Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoplatin plus gemcitabine vs gemcitabine in advanced pancreatic cancer
2011-003601-25Phase 3Withdrawn
- Sponsor
- Regulon, Inc.
- Start
- Feb 2012
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of lipoplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Regulon, Inc. Primary endpoints: One-year survival and Overall survival. Planned start Feb 2012; status: withdrawn.
02
Drugs
lipoplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-003601-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003601-25.